Inspiremd, INC 10-Q quarterly reports

InspireMD reports increased net loss and substantial doubt about its ability to continue as a going concern, exacerbated by a product recall and Nasdaq listing concerns.

InspireMD, Inc. reported a 122% revenue increase for Q1 2026 driven by CGuard Prime's US launch, but faces substantial doubt about its ability to continue as a going concern.

InspireMD reports significant revenue growth in Q3 2025 driven by the US commercial launch of its CGuard Prime carotid stent system, despite increased net losses and ongoing liquidity concerns.

InspireMD reported a significant increase in net loss for Q2 2025, driven by higher operating expenses, despite securing key regulatory approvals and raising $40.1 million in new capital.

InspireMD's Q1 2025 results show stable revenue but increased net losses due to higher operating expenses related to U.S. expansion and R&D investments.

InspireMD saw a revenue increase of 16.3% in Q3 2024 compared to Q3 2023, but also experienced a significant rise in net losses.

InspireMD's Q2 2024 results show increased revenue but a larger net loss due to higher operating expenses, alongside positive one-year follow-up data from their C-GUARDIANS trial.

InspireMD's first quarter 2024 results show a 22% increase in revenue year-over-year, but also a significant rise in operating expenses leading to a larger net loss.